Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amsilverstat B
- Development stage
- Unknown
- Lead developer
- Jiangsu Ke Feiping Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Amsilverstat B (also known as Ampsitat B) is a small molecule matrix metalloproteinase (MMP) inhibitor developed by Jiangsu Ke Feiping Pharmaceutical for the treatment of acute ischemic stroke. The drug primarily targets MMP-2 and MMP-9, which are enzymes involved in the degradation of the extracellular matrix and the breakdown of the blood-brain barrier (BBB) following an ischemic event. By inhibiting these proteases, amsilverstat B aims to reduce neuroinflammation, brain edema, and the risk of hemorrhagic transformation, thereby providing neuroprotection and improving clinical outcomes. The candidate has been evaluated in Phase 1 safety and pharmacokinetic studies in healthy volunteers and has progressed to Phase 2 clinical trials in patients with acute ischemic stroke in China.
- Other names
- Ampsitat B安普司他B
02
Targets
MMP2 (Matrix metalloproteinase-2)MMP9 (Matrix metalloproteinase-9)
Beyond the preview
Go deeper on amsilverstat B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amsilverstat B.